title: The metabolic syndrome: what to treat, how to treat, what are the goals?
abstract: Metabolic syndrome is a cluster of risk factors for cardiovascular disease that include obesity, atherogenic dyslipidemia, raised blood pressure, and insulin resistance. The growing trend of obesity is associated with increased prevalence of metabolic syndrome. Optimizing diet and exercise are still the leading therapy for controlling the metabolic syndrome. Based on the current evidence, further emphasis should be placed on aggressive management of other metabolic risk factors such as high blood pressure and dyslipidemia.
authors.affiliation: Johns Hopkins Ciccarone Preventive Cardiology Center, Division of Cardiology, The Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
authors.forename: Parin
authors.initials: P
authors.lastname: Parikh
authors.forename: Rahul
authors.initials: R
authors.lastname: Garg
authors.forename: Andrew
authors.initials: A
authors.lastname: Atiemo
authors.forename: Chandrasekhar R
authors.initials: CR
authors.lastname: Vasamreddy
authors.forename: Vicki
authors.initials: V
authors.lastname: Chan
authors.forename: Roger S
authors.initials: RS
authors.lastname: Blumenthal
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004032:Diet; D015444:Exercise; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016540:Smoking Cessation
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors